NuVasive, Inc. (NASDAQ:NUVA) medical device provider reported financial results for third quarter.
Company’s shares recovered some of their recent losses as the company said it is aggressively moving to replenish a diminished sales force that directed to flat third-quarter sales growth in its spinal division. Company cut its outlooks for the yearciting it will take some time to rejuvenate its sales staff and add new customer accounts.
Chairman and Chief Executive Officer of the Company Alex Lukianov said that market challenges commanded third quarter results to tumble down of the expectations.
NuVasive, Inc. (NASDAQ:NUVA) traded with volume of 4,114,200 shares in last session which was unexpectedly higher versus average trading capacity of 1.08 million shares. The stock traded with opening bell at $12.98, gained the maximum price level of $14.95 and then finished the day at $14.27 by scoring +12.81%.
NUVA remained successful in generating revenue of $589.18 million in the trailing twelve months and made net income of -$74.05 million. The Company maintained a negative -12.72% for the net profit margin and in its operating margin it scored -13.72%. Company’s yearly revenue change for the last five years was +40.68%.
The NUVA’s price to sales ratio is 1.05 and price to cash ratio is 2.57 for the past 12 months. As far as the returns from the company is concerned, return on assets remained as -6.14%.
The stock showed upbeat performance of +2.29% for the week which was maintained for the month at -36.80%. Likewise the negative performance for the trailing 3 months was recorded as -34.09% and in last year was -30.04% while the performance so far in current year remains at +13.34%.
Disclaimer
Fast Moving Stock does not own any shares or plan to get a position(s) in the company(s) anytime soon. Moreover, we have not been compensated for the posting of this article/report/analysis, as this is just an opinion of our writer/contributor. Not recommandation to buy or sell any stocks Read full
